Effect of deoxyfructoserotonin (DFS) on lepromatous leprosy.
To examine the anti-leprosy effect of deoxyfructoserotonin the drug was given in a dose of 10 mg/kg for 6 months to 6 patients with active lepromatous leprosy, in accordance with the WHO-THELEP protocol. Clinical and histological assessment and mouse foot-pad studies suggest that the drug has some anti-leprosy effect.
D000328:Adult; D001706:Biopsy; D002214:Capsules; D002986:Clinical Trials as Topic; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000652:urine; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012701:Serotonin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D002214:Capsules; D007917:Leprostatic Agents; D012701:Serotonin; C018901:desoxyfructo-serotonin; D007538:Isoniazid